Form 4: Jazz Pharma Director's RSU Vesting & Tax Sale

A Jazz Pharmaceuticals director acquired restricted stock units and sold shares to cover tax obligations from a prior vesting event.

Summary

• Patrick G. Enright, a Director of Jazz Pharmaceuticals plc, acquired 3,507 ordinary shares on August 7, 2025, through the vesting of restricted stock units (RSUs).
• These RSUs were granted under the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan and represent a contingent right to receive one ordinary share per unit upon vesting.
• The 3,507 units are subject to continuous service and certain conditions, and are scheduled to vest in full on July 24, 2026.
• On August 8, 2025, Mr. Enright disposed of 1,805 ordinary shares at a price of $111.2491 per share.
• This sale was conducted to satisfy tax obligations arising from the vesting of previously granted restricted stock units.
• Following these transactions, Mr. Enright beneficially owns 26,379 ordinary shares directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The transactions are routine insider compensation events (RSU vesting and subsequent tax-related sale) and do not reflect a discretionary buy or sell decision based on the director's outlook on the company's performance.

Positives

• The acquisition of 3,507 restricted stock units indicates ongoing equity compensation for a director, aligning their interests with shareholders.

Negatives

• The sale of 1,805 shares, while for tax purposes, reduces the director's direct ownership in the company.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This Form 4 filing details a routine insider transaction for a director of Jazz Pharmaceuticals, a biopharmaceutical company. Such transactions, particularly those related to RSU vesting and tax withholding, are common across the pharmaceutical and biotechnology industries as part of executive and director compensation structures.

Stakeholder Impact

• Shareholders: The director's ownership stake slightly decreased due to the tax-related sale, but the acquisition of new RSUs aligns future interests. This is a common occurrence and generally has minimal direct impact on other shareholders.

Key Dates

Keywords

Jazz Pharmaceuticals, JAZZ, SEC Form 4, Insider Trading, Restricted Stock Units, RSU, Director Compensation, Stock Sale, Tax Obligations